China Biotech Services Holdings Limited provided consolidated earnings guidance for the six months ending 30 June 2022. For the period, the company expected to record a net profit attributable to the owners of the Company of not less than HKD 65,000,000 for the 2022 Interim Period as compared with that of approximately HKD 24,230,000 recorded for the corresponding period in 2021. It represented an increase of Net Profit for more than 1.68 times on a year-on-year basis.

The Board considers that such an increase of the Net Profit for 2022 Interim Period was mainly attributable to (i) the robust demands for rapid antigen test kits and COVID-19 testing services during the period due to the raging fifth wave of COVID-19 pandemic; and (ii) the increase in demand for COVID-19 testing services from cross-border or overseas passengers due to the easing of border restrictions.